News and Events
News and Events
You may sort news and events by title or recency. If you wish to view only news, please select the news link from the left. If you wish to see events at which Quintiles is scheduled to participate, please select the events link from the left.
- Sort by: Most Recent
- Title
-
QUINTILES SIGNS AGREEMENT WITH CHINESE PHARMACEUTICAL COMPANY TO CONDUCT CLINICAL RESEARCH FOR HERBAL PRODUCT TO TREAT S
November 12, 1999 - Quintiles Transnational Corp. (Nasdaq: QTRN) today signed an agreement with Shanghai Xingling Scientific and Technology Pharmaceutical Co., Ltd., to conduct clinical studies of Shanghai Xingling's product, a traditional Chinese medicine derived from the gingko tree, to determine its effectiveness as a treatment for stable angina. -
PHASE FORWARD AND QUINTILES SIGN AGREEMENT TO EXPAND USE OF INTERNET IN DRUG DEVELOPMENT
Oct. 27, 1999 - Phase Forward Incorporated today announced the signing of a worldwide software licensing and master services agreement with Quintiles Inc., the product development service group of Quintiles Transnational Corp. (Nasdaq:QTRN), to expand the use of the Internet to enhance the speed and quality of drug development. -
QUINTILES ACQUISITION OF PREMIER REGULATORY AFFAIRS CONSULTANCY STRENGTHENS SOUTH AFRICAN PORTFOLIO
October 4, 1999 - Quintiles Transnational Corp. (Nasdaq: QTRN) today announced the acquisition of Medicines Control Consultants Pty Ltd. (MCC), a South Africa-based pharmaceutical regulatory consulting group. -
PILOT THERAPEUTICS REACHES AGREEMENT WITH QUINTILES AND CRODA LEEK LTD
Aug. 24, 1999 - Pilot Therapeutics, Inc., a technology company spun-out of Wake Forest University in 1998, has entered into agreements with Quintiles Inc. and Croda Leek Ltd. for development of its first nutraceutical product for asthma. Pilot's nutraceutical products, called Ethical Nutraceuticals(TM), are natural products that are clinically proven safe and effective. Unlike pharmaceuticals, Pilot's Ethical Nutraceuticals(TM) do not require premarketing approval from the FDA. -
QUINTILES ACQUIRES PREMIER PROVIDER OF PHYSICIAN MEETINGS AND EDUCATIONAL EVENTS FOR PHARMACEUTICAL COMPANIES IN THE US
July 12, 1999 - Quintiles Transnational Corp. (Nasdaq: QTRN) today announced the acquisition of New Jersey-based Medcom, Inc., a leading provider of physician meetings and educational events to help pharmaceutical companies raise awareness of their products among healthcare professionals. -
DATATRAK AND QUINTILES SIGN AGREEMENT FOR DEPLOYMENT OF DUAL PLATFORM ELECTRONIC DATA CAPTURE TECHNOLOGY
June 30, 1999 - DataTRAK International, Inc. (Nasdaq: DATA) today announced a worldwide, 3-year, software license and master services agreement with Quintiles, Inc. The software agreement is mutually nonexclusive between DataTRAK, a leader in worldwide use of Electronic Data Capture (EDC) and Quintiles, Inc., the Product Development service group of Quintiles Transnational Corp. (Nasdaq: QTRN), the leading healthcare services company to the pharmaceutical industry. -
DRKOOP.COM AND QUINTILES LAUNCH SERVICE TO RECRUIT CLINICAL TRIAL PATIENTS ON THE INTERNET
June 28, 1999 - drkoop.com (Nasdaq: KOOP) and Quintiles Transnational Corp. (Nasdaq: QTRN) today announced the launch of the first interactive, consumer Internet resource to enable interested individuals to sign up on-line for possible participation in clinical drug trials via the www.drkoop.com Web site. -
QUINTILES TRANSNATIONAL TO ADD 500+ JOBS IN KANSAS CITY . . . COMPANY TO MAKE KANSAS CITY OPERATION A REGIONAL HUB
June 23, 1999 - Quintiles Transnational Corp. announced today its intent to locate a regional pharmaceutical product development hub in Kansas City, adding 530 jobs here over the next three years. -
QUINTILES ACQUIRES INTERNATIONALLY RENOWNED MINERVA MEDICAL TO EXPAND LATE-PHASE CLINICAL RESEARCH
June 1, 1999 - Quintiles Transnational Corp. (Nasdaq: QTRN) today announced the acquisition of Minerva Medical plc, a Scotland-based clinical research organization with an international reputation for patient recruitment and management of large primary-care clinical trials involving chronic diseases through its strong network of physician relationships. -
QUINTILES CNS AND BEST PRACTICE LLC FORM ALLIANCE FOR CENTRAL NERVOUS SYSTEM DRUG DEVELOPMENT CONSULTING
May 26, 1999 - Quintiles Central Nervous System (CNS) Therapeutics has formed a strategic consulting alliance with Best Practice LLC, a leading CNS drug development consulting group, Quintiles Transnational Corp. (Nasdaq: QTRN) announced today.